[{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Series C Financing","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.12,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ RA Capital Management"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Renaissance Capital","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Renaissance Capital"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CBP-307","moa":"S1P1 receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CBP-174","moa":"H3R","graph1":"Dermatology","graph2":"Phase I","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"CBP-201","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"CBP-201","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"S1p receptor agonist 1","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Jiangsu Simcere Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Rademikibart","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Jiangsu Simcere Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Jiangsu Simcere Pharmaceutical"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Rademikibart","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Rademikibart","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Rademikibart","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Connect Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Connect Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Rademikibart","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Connect Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connect Biopharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Connect Biopharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Connect Biopharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : CBP-201 (rademikibart) is an IL-4 alpha receptor Inhibitor Antibody drug candidate, which is being evaluated for the treatment of Moderate-to-Severe Asthma.

                          Brand Name : CBP-201

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 12, 2023

                          Lead Product(s) : Rademikibart

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : CBP-201 (rademikibart) is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα). It is in development for the treatment of atopic dermatitis (AD) and asthma.

                          Brand Name : CBP-201

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 11, 2023

                          Lead Product(s) : Rademikibart

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Under the agreement, Simcere will develop and commercialize Connect Biopharma’s CBP-201 (rademikibart), a human monoclonal antibody against IL-4Rα, in Greater China.

                          Brand Name : CBP-201

                          Molecule Type : Large molecule

                          Upfront Cash : $21.0 million

                          November 21, 2023

                          Lead Product(s) : Rademikibart

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Jiangsu Simcere Pharmaceutical

                          Deal Size : $141.0 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : CBP-201 (rademikibart) is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), and is in development in patients with moderate-to-severe atopic dermatitis (AD).

                          Brand Name : CBP-201

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 21, 2023

                          Lead Product(s) : Rademikibart

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : CBP-201 (rademikibart) is an inhibitory human monoclonal antibody against the IL-4Rα. It is being evaluated in phase 3 clinical trials for the treatment of Atopic Dermatitis.

                          Brand Name : CBP-201

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 20, 2023

                          Lead Product(s) : Rademikibart

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : CBP-307 (icanbelimod) is an once-daily, orally administered, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator in development for the treatment of ulcerative colitis (UC).

                          Brand Name : CBP-307

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 01, 2023

                          Lead Product(s) : S1p receptor agonist 1

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : CBP-201 is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), it is in development for the treatment of atopic dermatitis (AD) and asthma.

                          Brand Name : CBP-201

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 17, 2023

                          Lead Product(s) : CBP-201

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : CBP-201, is an antibody designed to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis and asthma. As an inhibitor of IL-4Rα, CBP-201 blocks inflammatory signaling by both IL-4 and IL-13.

                          Brand Name : CBP-201

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          December 30, 2022

                          Lead Product(s) : CBP-201

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : CBP-201 is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), a validated target for the treatment of several inflammatory diseases, including AD.

                          Brand Name : CBP-201

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 27, 2022

                          Lead Product(s) : CBP-201

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Primary endpoint of IGA of 0 or 1 with at least 2 grades of reduction at Week 16 from baseline was significantly greater for the CBP-201 (300 mg every two weeks) group with 30.3% of patients showing improvement compared to 7.5% for the placebo group (p <...

                          Brand Name : CBP-201

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 04, 2022

                          Lead Product(s) : CBP-201

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank